~~<i id='C2A702FCD2'><strike id='C2A702FCD2'><tt id='C2A702FCD2'><pre id='C2A702FCD2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：fashion 2025-09-27 10:03:45 - browse：83689

Acadia Pharmaceuticals said Monday that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial.

The negative outcome of the Phase 3 study represents a setback in the company’s efforts to expand the use of Nuplazid into the treatment of schizophrenia. The medicine is currently approved to treat hallucinations and delusions associated with Parkinson’s disease psychosis.

“We are disappointed the trial did not meet its primary endpoint given the significant unmet need in patients with negative symptoms of schizophrenia,” said Acadia CEO Steve Davis, in a statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Medicare has a new plan to address drug shortages

focus

Wikipedia

explore

focus

AhealthcareworkerfillsasyringewithPfizer'sCovid-19vaccine.LynneSladky/APNewdatareleasedThursdaybythe

WSS

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Group opposing PBM reform sets lobbying record

The Biogen Aduhelm mess could happen again

Problems with a popular proposal to regulate AI in health care

Sanders adds drug shortage policies to pandemic preparedness bill

Adopting new red light myopia treatments may be short

hotspot

Wikipedia

focus

Activists slam private health insurers over coverage restrictions

Updated Covid vaccine has 54% effectiveness, new study suggests

Heart attack and stroke risk calculators need revising

Key House panel plots a new health care package

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD: Venture capital, Gilead, and more M&A

The cancer drug shortage isn’t new — and neither are the solutions

Custom gene therapy hints at new path for rare disease treatments

How one medical school became remarkably diverse

The Biogen Aduhelm mess could happen again

Wikipedia

Medicare to cover more brain scans for Alzheimer’s patients

FDA approves RSV monoclonal antibody for infants, toddlers

Top private equity targets in 2023: cardiology, clinical trials, lasers

Cosmetics set for new safety regulation. Why the industry is on board

Doctors find melanoma drugs effective against rare brain cancer

340B reform proposal comes out of Senate working group

explore

focus

focus

focus